Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
arGEN-X Simple AntIBODY™ Platform Set to Transform Therapeutic Antibody Discovery and Development
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody™ platform, announces that it will provide an update on the development of this platform and its own antibody pipeline during the BIO-Europe Spring event in Barcelona (March 8-10, 2010).
Tim Van Hauwermeiren, the CEO of arGEN-X, will highlight a series of important technical breakthroughs during his presentation, demonstrating the Company’s SIMPLE Antibody™ platform delivering multiple, diverse, ultra-potent functional antibodies that are able to blanket any target, regardless of its complexity.
He will also outline the progress that arGEN-X has made in building its own pipeline with its lead product ARGX-109, which entered preclinical development less than 12 months from the start of the discovery process. ARGX-109 was chosen from a panel of 65 functional antagonists generated against IL-6, a cytokine that plays an important role in several autoimmune, inflammation and oncology indications.
arGEN-X’ SIMPLE Antibody™ Platform is based on the active immunization of outbred Camelids with target antigen to deliver antibodies whose variable regions are virtually identical to those of human antibodies. These variable domains are combined with human constant domains to generate full size, fully human therapeutic antibodies.
SIMPLE Antibodies routinely exhibit gold-standard potency and manufacturability without the need for additional engineering, making them an ideal starting point for a therapeutic antibody development program.
arGEN-X intends to use the SIMPLE Antibody™ platform to build its business by making its technology and know-how available to biopharmaceutical companies through selective strategic partnerships and adding more exciting programs to its preclinical portfolio.
Tim Van Hauwermeiren, the CEO of arGEN-X, will highlight a series of important technical breakthroughs during his presentation, demonstrating the Company’s SIMPLE Antibody™ platform delivering multiple, diverse, ultra-potent functional antibodies that are able to blanket any target, regardless of its complexity.
He will also outline the progress that arGEN-X has made in building its own pipeline with its lead product ARGX-109, which entered preclinical development less than 12 months from the start of the discovery process. ARGX-109 was chosen from a panel of 65 functional antagonists generated against IL-6, a cytokine that plays an important role in several autoimmune, inflammation and oncology indications.
arGEN-X’ SIMPLE Antibody™ Platform is based on the active immunization of outbred Camelids with target antigen to deliver antibodies whose variable regions are virtually identical to those of human antibodies. These variable domains are combined with human constant domains to generate full size, fully human therapeutic antibodies.
SIMPLE Antibodies routinely exhibit gold-standard potency and manufacturability without the need for additional engineering, making them an ideal starting point for a therapeutic antibody development program.
arGEN-X intends to use the SIMPLE Antibody™ platform to build its business by making its technology and know-how available to biopharmaceutical companies through selective strategic partnerships and adding more exciting programs to its preclinical portfolio.
